Finnian R. Mc Causland
Brian L. Claggett
Marc A. Pfeffer
Emmanuel A. Burdmann
Kai Uwe Eckardt
Andrew S. Levey
John McMurray, Australian Catholic UniversityFollow
Ajay K. Singh
Robert D. Toto
Mc Causland, F. R, Claggett, B. L, Pfeffer, M. A, Burdmann, E. A, Eckardt, K. U, Levey, A. S, McMurray, J., Remuzzi, G., Singh, A. K, Solomon, S., Toto, R. D & Parfrey, P. (2017). Change in hemoglobin trajectory and darbepoetin dose approaching end-stage renal disease: data from the trial to reduce cardiovascular events with aranesp therapy trial. American Journal of Nephrology,46(6), G. L. Bakris. 488-497. Switzerland: S. Karger AG. Retrieved from https://doi.org/10.1159/000485326
The pathogenesis of chronic kidney disease associated anemia is multifactorial and includes decreased production of erythropoietin (EPO), iron deficiency, inflammation, and EPO resistance. To better understand the trajectory of these parameters, we described temporal trends in hemoglobin (Hb), ferritin, transferrin saturation, C-reactive protein (CRP), and darbepoetin dosing in the Trial to Reduce cardiovascular Events with Aranesp Therapy (TREAT).
We performed a post hoc analysis of 4,038 participants in TREAT. Mixed effects linear regression models were used to determine the trajectory of parameters of interest prior to end-stage renal disease (EstherD). Likelihood ratio tests were used to determine the overall differences in biomarker values and differences in trajectories between those who did and did not develop EstherD.
Hb declined precipitously in the year prior to the development of EstherD (irrespective of treatment assignment), and was on average 1.15 g/dL (95% CI –1.26 to –1.04) lower in those who developed EstherD versus those who did not, at the time of EstherD/end of follow-up. Simultaneously, the mean darbepoetin dose and CRP concentration increased, while serum ferritin and transferrin saturations were >140 μg/L and 20%, respectively.
Our analyses provide descriptive insights regarding the temporal changes of Hb, darbepoetin dose, and related parameters as EstherD approaches in participants of TREAT. Hb declined as much as 1–2 years prior to the development of EstherD, without biochemical evidence of iron deficiency. The most precipitous decline occurred in the months immediately prior to EstherD, despite administration of escalating doses of darbepoetin and in parallel with an increase in CRP.
Mary MacKillop Institute for Health Research